Aytu BioPharma Management
Management criteria checks 2/4
Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 9.08 years. total yearly compensation is $708.00K, comprised of 83.3% salary and 16.7% bonuses, including company stock and options. directly owns 1.29% of the company’s shares, worth $201.50K. The average tenure of the management team and the board of directors is 1.7 years and 7.8 years respectively.
Key information
Josh Disbrow
Chief executive officer
US$708.0k
Total compensation
| CEO salary percentage | 83.3% |
| CEO tenure | 9.1yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.7yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Dec 31Aytu BioScience completes safety study in critically ill COVID-19 patients
Dec 28Aytu Bio raises 'bought deal' offering to $25M
Dec 11Aytu BioScience: The Barcode King Is Poised For An Epic Breakout
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | US$708k | US$590k | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$32m |
| Dec 31 2022 | n/a | n/a | -US$77m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | US$590k | US$590k | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | US$6m | US$545k | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | US$2m | US$608k | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$25m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | US$1m | US$330k | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | n/a | n/a | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | US$606k | US$303k | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$21m |
| Jun 30 2017 | US$1m | US$250k | -US$23m |
Compensation vs Market: Josh's total compensation ($USD708.00K) is about average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.
CEO
Josh Disbrow (48 yo)
9.1yrs
Tenure
US$708,000
Compensation
Mr. Joshua R. Disbrow, also known as Josh, serves as Chairman at Aytu Biopharma, Inc. He served as Chairman at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 until 2023 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.1yrs | US$708.00k | 1.29% $ 201.5k | |
| CFO, Secretary & Treasurer | 2.3yrs | US$522.84k | 0.17% $ 26.7k | |
| Chief Commercial Officer | 1.8yrs | US$540.05k | 0.41% $ 64.0k | |
| Vice President of People & Culture | 1.3yrs | no data | no data | |
| Chief Business Officer & President of Consumer Health | 1.5yrs | US$793.41k | 0.23% $ 36.0k | |
| Senior Vice President of Research & Development | no data | no data | no data | |
| Executive VP of Finance & Business Optimization | 1.5yrs | no data | no data |
1.7yrs
Average Tenure
48yo
Average Age
Experienced Management: AYTU's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 8.3yrs | US$708.00k | 1.29% $ 201.5k | |
| Independent Director | 1.8yrs | US$89.62k | 0.12% $ 19.2k | |
| Lead Independent Director | 7.8yrs | US$90.00k | 0.014% $ 2.1k | |
| Independent Director | 8.1yrs | US$70.00k | 0.15% $ 22.9k | |
| Independent Director | less than a year | US$3.31k | 0.14% $ 22.5k |
7.8yrs
Average Tenure
56yo
Average Age
Experienced Board: AYTU's board of directors are considered experienced (7.8 years average tenure).